Acurx Pharmaceuticals, Inc. (ACXP) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights significant progress in clinical trials, a favorable FDA one-trial requirement, and an extended patent, all potentially reducing time to market and enhancing IP protection. Financials show reduced losses and prudent expense management. The Q&A reinforces confidence in trial strategies and FDA alignment. Although macroeconomic challenges exist, the overall sentiment is positive, suggesting a potential stock price increase in the short term, especially if the market recognizes the strategic advancements and financial discipline.
Key Financial Performance
Cash $9.3 million as of March 31, 2026, compared to $7.6 million as of December 31, 2025. The increase was due to raising approximately $3.1 million of gross proceeds through purchases under its equity line of credit.
Research and Development Expenses $0.3 million for the 3-months ended March 31, 2026, compared to $0.6 million for the 3-months ended March 31, 2025, a decrease of $0.3 million. The decrease was primarily due to a decrease in manufacturing costs of $0.1 million and a decrease in consulting-related costs of $0.2 million as a result of prior year trial preparation-related expenses.
General and Administrative Expenses $1.4 million for the 3-months ended March 31, 2026, compared to $1.6 million for the 3-months ended March 31, 2025, a decrease of $0.2 million. The decrease was primarily due to a $0.1 million decrease in professional fees and a $0.1 million decrease in legal costs.
Net Loss $1.7 million or $0.62 per diluted share for the 3-months ended March 31, 2026, compared to $2.1 million or $2.15 per diluted share for the 3-months ended March 31, 2025. The decrease in net loss was due to the reasons previously mentioned, including reduced R&D and G&A expenses.
Shares Outstanding 3,389,106 shares as of March 31, 2026.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Ibezapolstat Clinical Trial Program: A new clinical trial program for ibezapolstat in patients with recurrent CDI (rCDI) was announced. The trial aims to position ibezapolstat as a new standard of care for treating acute CDI and preventing rCDI. Phase II results showed a 96% cure rate with no recurrence in 25 patients. The new trial includes an open-label pilot study for patients with multiple recurrent CDI and plans for a Phase III registration trial.
Preclinical Development of DNA Pol IIIC Compounds: New DNA Pol IIIC compounds in preclinical development showed potential for treating gram-positive infections, including MRSA, while preserving microbiome structure. These findings were presented at the ESCMID Global Congress.
Patent Portfolio Expansion: The Korean Patent Office granted a new patent covering DNA polymerase IIIC inhibitors, adding to Acurx's portfolio of 10 patents across multiple countries. A new U.S. patent extends protection to December 2039.
Financial Position: The company ended Q1 2026 with $9.3 million in cash, up from $7.6 million at the end of 2025. Additional funding was secured through equity line purchases and a direct offering.
Cost Management: R&D expenses decreased by $0.3 million compared to Q1 2025, primarily due to lower manufacturing and consulting costs. General and administrative expenses also decreased by $0.2 million.
FDA Guidelines Impact: The FDA's new guideline requiring only one pivotal trial for registration could accelerate ibezapolstat's approval process for acute CDI treatment.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Uncertainty: The company is navigating potential changes in FDA guidelines, such as the shift to a one-trial requirement for registration. While this could be favorable, the lack of formalization introduces uncertainty in clinical development timelines and approval processes.
Funding Challenges: The company is actively seeking funding opportunities for its Phase III clinical trial program for ibezapolstat. Limited financial resources could delay or hinder the progress of critical trials.
Macroeconomic Environment: The company acknowledges challenges in the broader macroeconomic environment, which could impact its operations and funding capabilities.
Intellectual Property Risks: Although the company has secured multiple patents, ongoing patent applications in various countries remain under review, posing potential risks to its intellectual property portfolio.
Market Competition: The company operates in a competitive sector focused on developing treatments for infectious diseases, which may impact its ability to capture market share and achieve commercial success.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Clinical Trials for Ibezapolstat: Acurx Pharmaceuticals is initiating a groundbreaking clinical trial program for ibezapolstat targeting recurrent C. difficile infections (rCDI). The trial begins with an open-label pilot study for patients with multiple rCDI episodes, followed by a planned Phase III registration trial upon favorable results. The company aims to seek FDA approval for treatment and prevention of rCDI under the FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs Guidance for Industry.
FDA Guidelines Impact: The FDA's recent announcement of a one-trial requirement for registration, if formalized, could allow Acurx to seek marketing approval for acute CDI with a single pivotal clinical trial, potentially accelerating the development timeline.
Intellectual Property Expansion: Acurx has secured a new patent from the Korean Patent Office covering DNA polymerase IIIC inhibitors, further strengthening its intellectual property portfolio. This complements existing patents in the U.S. and other countries, extending protection for ibezapolstat and other pipeline products.
Funding and Financial Resources: The company has secured additional funding through a registered direct offering and private placement, ensuring sufficient resources to conduct exploratory clinical trials for rCDI. Efforts to secure funding for Phase III trials in acute CDI are ongoing.
Preclinical Development: Acurx is advancing preclinical development of DNA polymerase IIIC inhibitors for other gram-positive infections, with promising results in achieving therapeutic plasma levels and reducing MRSA tissue burden while preserving microbiome diversity.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you walk through the steps to formalize the one-trial guidance and its applicability to ibezapolstat?
A:The guidance was formalized by the FDA as of last Friday night. The company has a meeting scheduled with the FDA to discuss its applicability to ibezapolstat. The guidance allows for one adequate and well-controlled trial with confirmatory evidence to meet the substantial evidence of effectiveness standard. The company believes it meets several criteria for confirmatory evidence, including mechanistic data, in vitro and animal efficacy data, and microbiome data.
Q:What is the purpose of the 20-patient open-label trial, and how does it differ from the Phase III trial?
A:The 20-patient trial focuses on patients with multiple recurrences of CDI, while the Phase III trial targets patients with a single episode or no more than one recurrence. The 20-patient trial is exploratory and aims to inform the design of the Phase III trial.
Q:How do acute CDI, recurrent CDI, and regular CDI differ in treatment?
A:Acute CDI requires a 10-day antibiotic treatment. Recurrent CDI occurs in 20-30% of patients due to conditions set up by the initial infection. The new FDA guidance also considers long-term prevention of disease, expanding opportunities for studying treatment and recurrence prevention.
Q:What is the importance of microbiome preservation in the new FDA guidance, and how will the company present its microbiome data?
A:Microbiome preservation is key but not an approvable claim. The company will present data showing that ibezapolstat is gentler on the microbiome compared to drugs like vancomycin, maintaining beneficial bacteria that suppress C. difficile growth. This supports the drug's pharmacology and potential to reduce recurrence.
Q:What are the parameters for the Phase III trial regarding recurrence measures, and will it involve head-to-head comparisons with other drugs?
A:The Phase III trial will follow patients for 1 month after treatment to assess recurrence, with additional follow-up for 2 months. The trial will not involve head-to-head comparisons with vancomycin or fidaxomicin but will consider data from other approved agents like VOWST and REBYOTA.
Q:How does the company plan to align its protocols with the FDA's emphasis on thoughtful selection of patient populations, especially elderly populations?
A:The company has expanded its population to include all ages and aims to show consistency across diverse subgroups, including age, geographic, racial, and ethnic diversity. This supports the notion of a single trial for approval.
Q:When can we expect the start of the rCDI trial?
A:The company is in start-up mode, contacting and qualifying sites. The first patient is expected to be enrolled by August.
Q:Review of Unclear Management Responses
A:None of the questions were avoided or lacked clarity. All responses were detailed and addressed the questions directly.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CDI population
CDI rCDI
CDI recurrence
Director
IBZ
IIIC compound
Phase III
QA
QIDP designation
addition
agent
composition matter
compound development
gram infection
inhibitor composition
label
level
matter method
method use
microbiome
month treatment
patent DNA
poster
price share
registration statement
series
share stock
standard
stock term
term warrant
treatment prevention
trial rCDI
warrant lieu
ACXP Transcript
Acurx Pharmaceuticals, Inc. (ACXP) Q1 2026 Earnings Call Transcript
Positive5-12
The earnings call highlights significant progress in clinical trials, a favorable FDA one-trial requirement, and an extended patent, all potentially reducing time to market and enhancing IP protection. Financials show reduced losses and prudent expense management. The Q&A reinforces confidence in trial strategies and FDA alignment. Although macroeconomic challenges exist, the overall sentiment is positive, suggesting a potential stock price increase in the short term, especially if the market recognizes the strategic advancements and financial discipline.
Acurx Pharmaceuticals, Inc. (ACXP) Q4 2025 Earnings Call Transcript
Unknown3-13
The earnings call presents a mixed picture: significant cost reductions and decreased net losses are positive, but there's uncertainty in trial timelines and management's vague responses in the Q&A. While financial health has improved, the lack of clear guidance and potential delays in trials temper optimism. The absence of a market cap makes it difficult to gauge stock volatility, suggesting a neutral sentiment with a potential slight positive shift if trial developments progress smoothly.
Acurx Pharmaceuticals, Inc. (ACXP) Q3 2025 Earnings Call Transcript
Unknown11-12
The earnings call reveals both positive and negative aspects. On the positive side, there are significant cost reductions and potential regulatory advantages for ibezapolstat, supported by FDA designations. However, the company faces financial sustainability issues, with ongoing net losses and uncertainties in partnership timelines. The Q&A section showed management's cautious optimism but lacked concrete timelines or commitments, which could dampen investor confidence. Given these mixed signals, the stock is likely to remain stable in the short term, resulting in a neutral market reaction.
Acurx Pharmaceuticals, Inc. (ACXP) Q2 2025 Earnings Call Transcript
Unknown8-12
The earnings call presents a mixed picture: financial performance shows improvement with reduced losses and expenses, yet funding challenges and macroeconomic conditions pose risks. Despite positive regulatory guidance and potential partnerships, the lack of specific feedback from the medical community and operational cost concerns temper optimism. The neutral sentiment reflects these balanced factors, with no clear catalyst for a strong price movement.
ACXP Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
